journal
https://read.qxmd.com/read/38616411/phase-1-placebo-controlled-single-ascending-dose-trial-to-evaluate-the-safety-pharmacokinetics-and-effect-on-altered-states-of-consciousness-of-intranasal-bpl-003-5-methoxy-n-n-dimethyltryptamine-benzoate-in-healthy-participants
#1
JOURNAL ARTICLE
James Jonathan Rucker, Claire Roberts, Mathieu Seynaeve, Allan H Young, Ben Suttle, Takahiro Yamamoto, Anna O Ermakova, Fiona Dunbar, Frank Wiegand
AIMS: To investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BPL-003, a novel intranasal benzoate salt formulation of 5-methoxy- N,N -dimethyltryptamine (5-MeO-DMT), in healthy participants. METHODS: In all, 44 psychedelic-naïve participants enrolled in the double-blind, placebo-controlled single ascending dose study (1-12 mg BPL-003). Concentrations of 5-MeO-DMT and its pharmacologically active metabolite, bufotenine, were determined in plasma and urine...
April 14, 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38605658/psychedelics-and-the-inner-healer-myth-or-mechanism
#2
JOURNAL ARTICLE
Joseph Peill, Miriam Marguilho, David Erritzoe, Tommaso Barba, Kyle T Greenway, Fernando Rosas, Christopher Timmermann, Robin Carhart-Harris
BACKGROUND: Reference to an intrinsic healing mechanism or an 'inner healer' is commonplace amongst psychedelic drug-using cultures. The 'inner healer' refers to the belief that psychedelic compounds, plants or concoctions have an intrinsically regenerative action on the mind and brain, analogous to intrinsic healing mechanisms within the physical body, for example, after sickness or injury. AIMS: Here, we sought to test and critique this idea by devising a single subjective rating item pertaining to perceived 'inner healing' effects...
April 12, 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38576151/exploring-clozapine-use-in-severe-psychiatric-symptoms-associated-with-autism-spectrum-disorder-a-scoping-review
#3
REVIEW
André Luiz Schuh Teixeira da Rosa, Olivia Sorato Bezerra, Luis Augusto Rohde, Ana Soledade Graeff-Martins
BACKGROUND: Patients with autism spectrum disorder (ASD) may experience severe psychiatric symptoms, often unresponsive to conventional pharmacological therapies, highlighting the need for more effective alternatives. AIMS: This study aims to map and synthesize evidence on the use of clozapine as a therapeutic option for managing severe psychiatric symptomatology co-occurring with ASD. METHODS: We conducted a scoping review on multiple sources following the JBI guidelines...
April 4, 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38532577/just-a-gut-feeling-faecal-microbiota-transplant-for-treatment-of-depression-a-mini-review
#4
REVIEW
Minna Chang, Kai Tuomas Chang, Fuju Chang
BACKGROUND: The microbiota-gut-brain axis (MGBA) allows bidirectional crosstalk between the brain and gut microbiota (GM) and is believed to contribute to regulating mood/cognition/behaviour/metabolism/health and homeostasis. Manipulation of GM through faecal microbiota transplant (FMT) is a new, exciting and promising treatment for major depressive disorder (MDD). AIMS: This mini-review examines current research into GM and FMT as a therapy for depression. METHODS: Original research articles published in Medline/Cochrane Library/PubMed/EMBASE/PsycINFO databases/National Institute of Health website Clinicaltrials...
March 26, 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38520287/impact-of-patient-specific-factors-on-clozapine-metabolism-in-individuals-with-treatment-resistant-schizophrenia-or-schizoaffective-disorder
#5
JOURNAL ARTICLE
Reza Rafizadeh, Anmol Sooch, Alessia Risi, Nicoline Bihelek, Kyler Kanegawa, Alasdair M Barr, Randall F White, Christian G Schütz, Chad A Bousman
BACKGROUND: There is high inter-individual variability in clozapine metabolism due to genetic and non-genetic differences. Patient-specific factors such as smoking, inflammation indicated by elevated C-reactive protein (CRP), and certain concurrent medications have a significant influence on clozapine metabolism. AIM: To assess which patient-specific factors best explain variability in clozapine metabolism estimated by clozapine concentration to dose (C/D) ratios...
March 23, 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38520045/effects-of-discontinuation-of-serotonergic-antidepressants-prior-to-psilocybin-therapy-versus-escitalopram-for-major-depression
#6
JOURNAL ARTICLE
David Erritzoe, Tommaso Barba, Meg J Spriggs, Fernando E Rosas, David J Nutt, Robin Carhart-Harris
BACKGROUND: There is growing evidence for the therapeutic effects of the psychedelic drug psilocybin for major depression. However, due to the lack of safety data on combining psilocybin with selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) and concerns that there may be a negative interaction on efficacy, participants enrolling in psychedelic trials are usually required to discontinue SNRI/SNRIs prior to enrolling. AIMS: Using data from a recent clinical trial examining the comparative efficacy the psychedelic drug psilocybin (P) combined with approximately 20 h of psychological support to a 6-week (daily) course of the SSRI escitalopram plus matched psychological support for major depressive disorder, we explored the effects of discontinuing SSRI/SNRIs prior to study enrolment on study outcomes...
March 22, 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38519421/the-pharmacokinetics-and-pharmacodynamics-of-ibogaine-in-opioid-use-disorder-patients
#7
JOURNAL ARTICLE
Thomas Knuijver, Rob Ter Heine, Arnt F A Schellekens, Paniz Heydari, Luc Lucas, Sjoerd Westra, Maarten Belgers, Toon van Oosteren, Robbert Jan Verkes, Cornelis Kramers
OBJECTIVE: Ibogaine is a hallucinogenic drug that may be used to treat opioid use disorder (OUD). The relationships between pharmacokinetics (PKs) of ibogaine and its metabolites and their clinical effects on side effects and opioid withdrawal severity are unknown. We aimed to study these relationships in patients with OUD undergoing detoxification supported by ibogaine. METHODS: The study was performed in 14 subjects with OUD. They received a single dose of 10mg/kg ibogaine hydrochloride...
March 22, 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38519416/effects-of-erythropoietin-on-cognitive-impairment-and-prefrontal-cortex-activity-across-affective-disorders-a-randomized-double-blinded-placebo-controlled-trial
#8
JOURNAL ARTICLE
Julian Macoveanu, Jeff Zarp Petersen, Johanna Mariegaard, Andreas Elleby Jespersen, Katrine Cramer, Caroline Fussing Bruun, Helle Østergaard Madsen, Martin Balslev Jørgensen, Maj Vinberg, Patrick M Fisher, Gitte Moos Knudsen, Ida Hageman, Hannelore Ehrenreich, Lars Vedel Kessing, Kamilla Woznica Miskowiak
BACKGROUND: Persistent cognitive impairment is frequent across bipolar disorder (BD) and major depressive disorder (MDD), highlighting an urgent need for pro-cognitive treatments. AIM: This study investigated effects of erythropoietin (EPO) on cognitive impairment and dorsal prefrontal cortex (dPFC) activity in affective disorders. METHODS: In this randomized, double-blinded, placebo-controlled trial, cognitively impaired patients with remitted BD or MDD received 1 weekly recombinant human EPO (40,000 IU/mL) or saline infusion for a 12-week period...
March 22, 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38494948/common-pitfalls-and-how-to-avoid-them-in-child-and-adolescent-psychopharmacology-part-i
#9
REVIEW
Samuele Cortese, Frank Mc Besag, Bruce Clark, Chris Hollis, Joe Kilgariff, Carmen Moreno, Dasha Nicholls, Paul Wilkinson, Marc Woodbury-Smith, Aditya Sharma
As Faculty of the British Association for Psychopharmacology course on child and adolescent psychopharmacology, we present here what we deem are the most common pitfalls, and how to avoid them, in child and adolescent psychopharmacology. In this paper, we specifically addressed common pitfalls in the pharmacological treatment of attention-deficit/hyperactivity disorder, anxiety, bipolar disorder, depression, obsessive-compulsive disorder and related disorders, and tic disorder. Pitfalls in the treatment of other disorders are addressed in a separate paper (part II)...
March 18, 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38494873/common-pitfalls-and-how-to-avoid-them-in-child-and-adolescent-psychopharmacology-part-ii
#10
REVIEW
Samuele Cortese, Frank Mc Besag, Bruce Clark, Chris Hollis, Joe Kilgariff, Carmen Moreno, Dasha Nicholls, Paul Wilkinson, Marc Woodbury-Smith, Aditya Sharma
As Faculty of the British Association for Psychopharmacology course on child and adolescent psychopharmacology, we present here what we deem are the most common pitfalls, and how to avoid them, in child and adolescent psychopharmacology. In this paper, we specifically addressed common pitfalls in the pharmacological treatment of autism and intellectual disability, eating disorders, neuropsychiatric correlates of epilepsy, and psychosis. Pitfalls in relation to the treatment of other disorders are addressed in a separate paper (Part I)...
March 17, 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38494791/a-proposal-for-reducing-maximum-target-doses-of-drugs-for-psychosis-reviewing-dose-response-literature
#11
REVIEW
James R O'Neill, Adam Jameson, Samantha L McLean, Michael Dixon, Alastair G Cardno, Christopher Lawrence
BACKGROUND: Presently, there is limited guidance on the maximal dosing of psychosis drugs that is based on effectiveness rather than safety or toxicity. Current maximum dosing recommendations may far exceed the necessary degree of dopamine D2 receptor blockade required to treat psychosis. This may lead to excess harm through cognitive impairment and side effects. AIMS: This analysis aimed to establish guidance for prescribers by optimally dosing drugs for psychosis based on efficacy and benefit...
March 17, 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38494658/proportion-of-antipsychotics-with-cyp2d6-pharmacogenetic-pgx-associations-prescribed-in-an-early-intervention-in-psychosis-eip-cohort-a-cross-sectional-study
#12
JOURNAL ARTICLE
Adam Jameson, Muhammad Faisal, Beth Fylan, Greg C Bristow, Jaspreet Sohal, Caroline Dalton, Gurdeep S Sagoo, Alastair G Cardno, Samantha L McLean
BACKGROUND: Prescribing drugs for psychosis (antipsychotics) is challenging due to high rates of poor treatment outcomes, which are in part explained by an individual's genetics. Pharmacogenomic (PGx) testing can help clinicians tailor the choice or dose of psychosis drugs to an individual's genetics, particularly psychosis drugs with known variable response due to CYP2D6 gene variants ('CYP2D6-PGx antipsychotics'). AIMS: This study aims to investigate differences between demographic groups prescribed 'CYP2D6-PGx antipsychotics' and estimate the proportion of patients eligible for PGx testing based on current pharmacogenomics guidance...
March 17, 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38481078/specific-adverse-outcomes-associated-with-selective-serotonin-reuptake-inhibitors-use-in-covid-19-patients-might-be-potentiated-by-remdesivir-use
#13
JOURNAL ARTICLE
Ivan Papic, Petra Bistrovic, Ivan Krecak, Maja Ortner Hadziabdic, Marko Lucijanic
BACKGROUND: Due to non-consistent reports in the literature, there are uncertainties about the potential benefits and harms of selective serotonin reuptake inhibitors (SSRIs) in patients with Coronavirus disease 2019 (COVID-19). AIM: To investigate associations of SSRIs with clinical characteristics and unwanted outcomes among real-life severe and critical COVID-19 patients and their relationship with remdesivir (RDV) use. METHODS: This retrospective cohort study evaluated a total of 1558 COVID-19 patients of the white race treated in a tertiary center institution, among them 779 patients treated with RDV and 779 1:1 case-matched patients...
March 13, 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38477185/brain-derived-neurotrophic-factor-val66met-and-cyp2b6-polymorphisms-as-predictors-for-ketamine-effectiveness-in-patients-with-treatment-resistant-depression
#14
JOURNAL ARTICLE
Nelson B Rodrigues, David Chen-Li, Joshua D Di Vincenzo, Ashwin Juneja, Benjamin D Pinder, Roger S McIntyre, Joshua D Rosenblat
BACKGROUND: Converging lines of evidence indicate that ketamine is a rapid antidepressant for individuals with treatment-resistant depression. Hitherto, no reliable a priori predictors of ketamine response have been reported. Pharmacogenetic biomarkers have yielded mixed results regarding potential candidate genes associated with ketamine's biochemistry as reliable predictors of response. AIMS: No studies have examined the effects of Val66Met and CYP2B6 genotypes on patients receiving repeated infusions of intravenous ketamine...
March 13, 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38418434/the-neural-oscillations-serving-task-switching-are-altered-in-cannabis-users
#15
JOURNAL ARTICLE
Kellen M McDonald, Mikki Schantell, Lucy K Horne, Jason A John, Maggie P Rempe, Ryan Glesinger, Hannah J Okelberry, Anna T Coutant, Seth D Springer, Amirsalar Mansouri, Christine M Embury, Yasra Arif, Tony W Wilson
BACKGROUND: Regular cannabis is known to impact higher-order cognitive processes such as attention, but far less is known regarding cognitive flexibility, a component of executive function. Moreover, whether such changes are related to aberrations in the neural oscillatory dynamics serving flexibility remains poorly understood. AIMS: Quantify the neural oscillatory dynamics serving cognitive flexibility by having participants complete a task-switching paradigm during magnetoencephalography (MEG)...
February 28, 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38409664/in-memoriam-professor-brian-leonard-1936-2023
#16
EDITORIAL
John P Kelly, John F Cryan, David P Finn
No abstract text is available yet for this article.
February 26, 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38385351/the-effect-of-psychedelics-on-the-level-of-brain-derived-neurotrophic-factor-a-systematic-review-and-meta-analysis
#17
JOURNAL ARTICLE
Arman Shafiee, Razman Arabzadeh Bahri, Mohammad Ali Rafiei, Fatemeh Esmaeilpur Abianeh, Parsa Razmara, Kyana Jafarabady, Mohammad Javad Amini
BACKGROUND: Recent interest in the potential therapeutic effects of psychedelics has led to investigations into their influence on molecular signaling pathways within the brain. AIMS: Integrated review and analysis of different studies in this field. METHODS: A systematic search was conducted across international databases including Embase, Scopus, Web of Science, and PubMed from inception to 9 July 2023. Eligibility criteria encompassed published and peer-reviewed studies evaluating changes in brain-derived neurotrophic factor (BDNF) levels after psychedelic consumption...
February 22, 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38332661/mifepristone-decreases-nicotine-intake-in-dependent-and-non-dependent-adult-rats
#18
JOURNAL ARTICLE
Ranjithkumar Chellian, Azin Behnood-Rod, Adriaan W Bruijnzeel
BACKGROUND: Addiction to tobacco and nicotine products has adverse health effects and afflicts more than a billion people worldwide. Therefore, there is an urgent need for new treatments to reduce tobacco and nicotine use. Glucocorticoid receptor blockade shows promise as a novel treatment for drug abuse and stress-related disorders. AIM: These studies aim to investigate whether glucocorticoid receptor blockade with mifepristone diminishes the reinforcing properties of nicotine in rats with intermittent or daily long access to nicotine...
February 8, 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38332655/a-semi-naturalistic-open-label-study-examining-the-effect-of-prescribed-medical-cannabis-use-on-simulated-driving-performance
#19
JOURNAL ARTICLE
Brooke Manning, Thomas R Arkell, Amie C Hayley, Luke A Downey
BACKGROUND: Despite increasing medical cannabis use, research has yet to establish whether and to what extent products containing delta-9-tetrahydrocannabinol (THC) impact driving performance among patients. Stable doses of prescribed cannabinoid products during long-term treatment may alleviate clinical symptoms affecting cognitive and psychomotor performance. AIM: To examine the effects of open-label prescribed medical cannabis use on simulated driving performance among patients...
February 8, 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38327032/selective-orexin-1-receptor-antagonism-does-not-affect-effort-based-responding-for-sucrose-reward-in-rats
#20
JOURNAL ARTICLE
Giorgio Bergamini, Sean Durkin, Michel Alexander Steiner
In rodents, orexin neuropeptides regulate motivation and reward-seeking via orexin 1 receptor (OX1R) signaling in the mesolimbic dopaminergic system. This role is clearly established for rewards inherent to drugs of abuse but less so for natural rewards. Reported effects of the selective OX1R antagonist (SO1RA) SB-334867 on motivation for palatable food are ambiguous. In our experimental conditions neither SB-334867, nor two additional, structurally different SO1RAs, ACT-335827 and the clinical development candidate nivasorexant, affected effort-based responding for sucrose in rats...
February 7, 2024: Journal of Psychopharmacology
journal
journal
30126
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.